Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept Plus Cyclosporine in Newly Diagnosed NSAA
NCT05399732Phase 2Completed
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luspatercept in aplastic anemia (2 arms). Primary endpoint: Overall Response Rate at 6 months. Started Dec 2022; status: completed.
02
Drugs
luspatercept
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05399732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399732.